Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 09 - 06 tags : Drug save search
Disease-Modifying Antirheumatic Drug (DMARD) Market to Surpass US$ 27,167.8 Million by 2030 - Coherent Market Insights
Published: 2022-09-06 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: 0.0%
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: 0.73%
H: 2.28%
C: 1.72%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.65%
H: 0.93%
C: 0.71%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.03%
H: 1.18%
C: 0.13%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.03%
H: 1.08%
C: 0.84%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.44%
H: 2.03%
C: 1.76%
CPIX | $1.65 6.02% 790
|
Health Technology
|
| O: -4.52%
H: 7.12%
C: 5.69%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.24%
H: 1.04%
C: 0.82%
drug market
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
Published: 2022-09-06 (Crawled : 18:00) - biospace.com/
TNYA | $4.31 0.47% 0.46% 410K
|
|
| O: 4.17%
H: 0.77%
C: -10.95%
tn-301 fda clearance drug heart application therapeutics study
Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader– Phase 1/2 Clinical Trial in Patients with MYC-driven Solid Tumors Expected to Dose in Q4 2022 –
Published: 2022-09-06 (Crawled : 18:00) - biospace.com/
GLUE | $5.84 -1.35% -1.37% 110K
|
Professional, Scientific, and T...
|
| O: 3.72%
H: 1.43%
C: -2.51%
mrt-2359 fda clearance drug rosa application expected trial therapeutics molecular
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
PSTV | $1.67 -1.27% -1.28% 25K
|
Health Technology
|
| O: -1.16%
H: 0.61%
C: -11.11%
fda drug candidate meeting therapeutics plus
Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Published: 2022-09-06 (Crawled : 13:00) - prnewswire.com
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 0.0%
H: 1.66%
C: -3.5%
wp1122 treatment fda designation drug glioblastoma
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
Published: 2022-09-06 (Crawled : 12:20) - globenewswire.com
SPRO | $1.41 -4.08% -4.26% 380K
|
Health Technology
|
| O: 14.94%
H: 127.46%
C: 35.28%
drug meeting program therapeutics food update
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2022-09-06 (Crawled : 12:00) - prnewswire.com
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 1.38%
H: 1.38%
C: -5.47%
treatment awards drug grant t-cell food study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.